However, patients with dMMR/MSI-H CRC account for 5% of all metastatic CRC, while the large majority of patients have a microsatellite-stable (MSS) disease that does not benefit from anti-PD-1/PD-L1 therapy. The gene discussed is PDCD1; the disease is colorectal carcinoma.